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Back ground  
Systematic reviews have concluded that hrHPV DNA testing using target-amplification tests 
is as accurate on vaginal self-samples as on clinician-taken specimens for the detection of 
cervical precancer. However, insufficient evidence is available for specific HPV assay/self-
sample device combinations. 
Objectives 
The VALHUDES protocol is designed as a diagnostic test accuracy study that aims to compare 
the clinical sensitivity and specificity of particular hrHPV assay(s) on vaginal self-samples and 
first-void-urine, collected in agreement with standardized protocols, with hrHPV testing on 
matched clinician-taken samples. 
Study design 
Five hundred enrolled women referred to a colposcopy clinic are invited to collect a first-void 
urine sample and one or more vaginal self-samples with particular devices before collection of 
a cervical sample by a clinician. Sample sets are subsequently analysed in a laboratory 
accredited for HPV testing. Disease verification for all enrolled patients is provided by 
colposcopy combined with histological assessment of biopsies. 
Results 
A first VALHUDES study has started in Belgium in December 2017 with enrolment from four 
colposcopy centres. The following assays are foreseen to be evaluated: RealTime High Risk 
 2 
VALHUDES a protocol for VALidation of HUman papillomavirus assays and collection 
DEvices for HPV testing on Self-samples and urine samples 
HPV assay (Abbott), cobas-4800 and -6800 (Roche), Onclarity (BD), Xpert HPV (Cepheid) 





Given empirical evidence that the relative accuracy of HPV-testing on self- vs clinician-
samples is robust across clinical settings, the VALHUDES protocol offers a framework for 






Offering devices which allow women to take a self-sample may increase uptake for cervical 
cancer screening among particularly those who do not participate in the regular programme. 
Several studies have shown that mailing a self-sampling kit to the women's home address 
generates a greater response compared to mailing of reminder letters recommending collection 
of a cervical sample by a health professional[1,2]. However, the magnitude of this response 
gain is very heterogeneous across studies, which suggests that the impact of self-sampling 
depends on local conditions, context and the design of the screening programme[2]. 
Implementation of strategies using self-sampling without knowledge of possible effects and 
influencing factors may result in small gains in population coverage but substantial costs for 
the health budget[3,4]. The opt-in approach where non-attending women are invited to order a 
self-sampling device is designed to reduce waste of self-sampling devices and thereby reduce 
cost of operations[5,6]. However, systematic reviews of randomised trials indicate that opt-in 
strategies generate lower participation rates compared with mail-to-all strategies[2,5,7]. 
Nevertheless, several demonstration studies using opt-in strategies were successful as well in 
mobilising women who did not respond to an invitation to have a Pap smear taken by a clinician 
overall generating a considerable prevention effect[6,8]. Whether a mail-to-all or opt-in 
approach is chosen, finding validated and safe procedures using devices which are affordable, 
easy to mail, acceptable, user-friendly, technically robust and compatible with used DNA 
extraction and detection methods are of paramount importance[9,10][11].  
 
An increasing number of human papillomavirus (HPV) tests are now considered as acceptable 
for use in primary cervical cancer screening on clinician-collected cervical cell samples[12-
14]. A recent meta-analysis demonstrated that high-risk (hr) HPV assays, based on a principle 
of signal-amplification were significantly less sensitive and specific for underlying high-grade 
cervical intra-epithelial neoplasia (CIN of grade 2 or worse [CIN2+]) on self-samples than on 
clinician-taken samples. However, testing withPCR-based hrHPV assays, already validated on 
clinician-taken samples[14], showed similar accuracy on vaginal self-samples compared to 
cervical samples taken by a health professional[15,16]. Sub-group meta-analysis did not reveal 
important self-sampling device effects, with the caveat that most studies directly compared the 
performance of (only) one particular self-sampling device with clinician-collected specimens, 
and as such no strong conclusions could be drawn regarding the impact or lack of impact of 
the choice of the self-samplers on the test accuracy. 
 
Among methods for self-sampling, collection of urine samples is to be considered as well. 
Urine sampling is in some context more culturally and religiously acceptable than cervico-
vaginal based self-sampling[17]. A recent review assessed the analytical sensitivity and 
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specificity of hrHPV testing in urine using presence of hrHPV in a clinician-collected cervical 
sample as endpoint[18]. The pooled sensitivity and specificity estimates were 77% (95% CI: 
68-84%) and 88% (95% CI: 58-97%), respectively. Findings were however, very variable (high 
inter-study heterogeneity, and included a mixture of clinical settings [screening, follow-up, age 
ranges, random or first-void collection, procedures for sample handling, etc.]. In addition, very 
few data on clinical accuracy of hrHPV testing on urine specimens are available. The few 
studies which have assessed the clinical sensitivity for CIN2+ have shown lower clinical 
sensitivity of hrHPV testing in urine than in cervical samples[19,20]. In these studies, urine 
sample collection may have been suboptimal for the detection of HPV given recent evidence 
focusing on the capture of a first-void specimen as well as addition of preservation buffers 
which together has the potential to significantly enhance the sensitivity of hrHPV DNA 
detection in urine[21-25].  
 
OBJECTIVES 
The VALHUDES project aims to provide high quality comparative data on clinical 
performance of HPV testing on self-collected samples. The current protocol compares the 
clinical accuracy of hrHPV testing with defined, clinically validated PCR-based hrHPV assays 
on vaginal self-samples collected with various devices and on first-void urine, collected under 




The main objective of VALHUDES is to assess whether HPV testing on vaginal self-samples 
or a first-void urine specimen, using a particular self-sampler, is as accurate as HPV testing on 
a cervical sample taken by a clinician to detect cervical precancer. Secondary objectives 
include the assessment of the absolute accuracy of each HPV test applied according to each 
sampling device, the proportion of adequate specimens as determined by amplification of an 
internal control (an ubiquitous human gene), the test positivity rate, relative and absolute 
predictive values. CIN2+ and CIN3 or cervical carcinoma in situ or worse (CIN3+) are the 
disease outcomes.  
 
Study design 
VALHUDES is designed as a diagnostic test accuracy study following the STARD 
guidelines[26], where all subjects are tested independently with an index and a comparator test 
and subsequently are submitted to a reference or gold standard. Collections of specimens used 
for testing and verification of disease status occur quasi simultaneously. The index tests are an 
HPV assay applied on a vaginal self-sample and on a first-void urine specimen, whereas the 
comparator test is the same HPV assay applied on a cervical liquid-based cytology sample 
collected by a trained clinician. Disease verification entails colposcopy applied to all women 
followed by colposcopy-directed biopsy. In case of multiple biopsy episodes, the worst 
histological outcome will be recorded. Negative colposcopy is accepted as providing sufficient 
ascertainment for absence of cervical precancer. 
 
Study population and clinical setting  
Women attending a colposcopy clinic referred due to previous cytological abnormalities, HPV 
infection or because of suspicious symptoms will be enrolled after obtaining informed consent. 
From a previous meta-analysis, it was concluded that the relative sensitivity and specificity of 
HPV testing on self-taken compared to clinician-collected samples were similar in screening 
and follow-up settings. For reasons of statistical power, it is more convenient to conduct a 
diagnostic trial in a colposcopy setting, where all women are referred for diagnostic evaluation 
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and where the application of the gold standard is required for clinical reasons (rather than a 
study-driven intervention). This minimises the requirement for additional interventions beyond 
standard of care and, additionally, biases induced by partial diagnostic verification are avoided. 
Exclusion criteria are: women younger than 25 or older than 64, hysterectomised women, 
women with known pregnancy at consultation and non-consenting women and inability to 
understand the patient materials and informed consent form. 
 
Study size 
The sample size was computed using a method for demonstrating non-inferiority in studies 
with matched design[27]. Expected probabilities (sensitivity or specificity of the standard test 
= hrHPV with validated PCR in follow-up settings) were derived from a recent meta-
analysis[15]. Expected discordance (hrHPV positivity/negativity) of hrHPV PCR on self-
samples taken with the new device vs Evalyn Brush (Rovers Medical Devices B.V., Oss, The 
Netherlands) were derived from a study conducted in Hannover[28]. We accepted alpha=0.05, 
beta=0.20, lower confidence interval for relative sensitivity and specificity 
(index/comparator)=0.90 and 0.95, respectively, which yielded a need to enrol 118 CIN2+ 
cases and 183 ≤ CIN1 cases. The yearly number of referred patients, the proportion accepting 
enrolment in the study, the biopsy rate (proportion biopsied among women undergoing 
colposcopy), the expected prevalence of CIN2+ and ≤CIN1 have to be taken into account, to 
determine the required sample size in a specific colposcopy clinic. The non-inferiority in 
sensitivity for CIN2+ is expected to determine the study size, rather than the specificity. 118 
CIN2 cases are expected to be retrievable among 353 participating colposcopy patients with 
biopsy. As a template we can put forward 500 included colposcopy patients, absorbing most 
assumptions and local statistics. 
 
Evaluated tests and devices 
In the first VALHUDES study, conducted in Belgium, the following collection procedures are 
foreseen: a) first-void urine collection using the Colli-Pee device (Novosanis NV, Wijnegem, 
Belgium) one day before the colposcopy visit; b) vaginal self-sampling with Multi-Collect 
Swab (Abbott Molecular, Inc., Des Plaines, IL, USA), c) vaginal self-sampling of half of the 
study population with Evalyn Brush and the other half with Qvintip (Aprovix AB, Uppsala, 
Sweden) at the colposcopy centre and d) the collection of a cervical liquid-based cytology 
sample by a gynaecologist using the Cervex-Brush (Rovers Medical Devices) as recommended 
in the European guidelines for preparation of cervical liquid-based cytology samples[29]. After 
collecting cervical epithelial cells, the Cervex-Brush will be pressed vigorously against the 
bottom of a vial containing 20 mL PreservCyt (Hologic Inc., Bedford, MA, USA) to remove 
all the cellular material. 
 
The dry self-sampling devices will be transferred after arrival in the laboratory into a storage 
medium: the Multi-Collect Swab into Abbott Cervi-Collect buffer and the Evalyn Brush or 
Qvintip into PreservCyt. Colli-Pee is a non-invasive self-sampling device for collection of the 
first 20 mL of urine (first-void) from women or men. The collector is prefilled with a solution 
of Urine Conservation Medium (UCM) buffer appropriate for molecular testing for detection 
of infectious agents such as HPV[22]. Detailed user instructions for the Colli-Pee, Multi-
Collect Swab, Evalyn-Brush and Qvintip can be found in the Belgian VALHUDES protocol in 
the Supplementary Appendix.  
 
The first assays that will be evaluated are the Abbott RealTime High Risk HPV assay(Abbott 
GmbH & Co. KG, Wiesbaden, Germany)[30-32], and the cobas 4800 and 6800 (Roche 
Molecular System, Pleasanton, CF, USA)[33,34] which identify DNA of the L1 gene of 
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HPV16 and HPV18 separately and the pool of 12 other hrHPV types (31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68). In addition, the RIATOL qPCR HPV genotyping assay[35] will be 
evaluated, which identifies DNA of the E6/E7 genes of the same 14 hrHPV types, separately, 
as well as HPV types 6, 11 and 53 and the L1 gene of HPV67. All these assays use the 
amplification of the beta-globin gene as a sample validity or process control. 
  
Aliquotting and further testing of archived VALHUDES specimens 
Residual material of all VALHUDES specimen will be aliquoted and stored, as explained in 
the Supplementary Appendix, following procedures and agreements with laboratories and 
manufactures as applied previously in the VALGENT framework, used for validation of HPV 
genotyping tests applied on clinician-taken samples[36].  
 
Attitudes and acceptance by women 
The attitudes and preferences of eligible women can be evaluated by questionnaires (see 
Supplementary Appendix). Response rates (proportion of approached women that accept to 
participate in the study) will be used to monitor the enrolment statistics. 
 
Future VALHUDES studies 
Other assays expected to be evaluated through the Belgian VALHUDES framework are: BD 
Onclarity HPV Assay (BD Diagnostics, Sparks, MD, USA)[37], Xpert HPV Assay (Cepheid, 
Sunnyvale, USA)[38], and Anyplex II HPV HR (Seegene, Seoul, Korea)[39,40]. Additional 
assays may be included as long as residual aliquots are available. 
 
More VALHUDES studies will be conducted in other countries and will include other self-
sample device/storage medium/HPV assay combinations. This will generate a uniquely rich 
database that will allow further meta-analytical pooling and form a framework for universal 
validation and comparison of HPV assays on self-samples (vaginal or urine).  
 
RESULTS 
The Belgian VALHUDES has started in December 2017 and will enrol women from four 
colposcopy centres (University Hospitals of Antwerp, Brussels and Ghent and Heilig-Hart 
Hospital of Tienen). The protocol was approved by the Ethical Boards of the respective study 
centres. Residual cervical and vaginal material will be archived in the AML laboratory whereas 
residual first-void urine samples will be archived in the Centre for the Evaluation of 
Vaccination (CEV) at the University of Antwerp. Colposcopy and biopsy results will be 
obtained from the four colposcopy centres and there affiliated histopathology laboratories. The 
Unit of Cancer Epidemiology of the Belgian Cancer Centre (Sciensano, Brussels) will 
coordinate the study and perform statistical analyses. An interim analysis after assessment of 
samples from 100 women and a final analysis after assessment of all 500 samples are foreseen 
in mid-2018 and early 2019, respectively. 
 
DISCUSSION 
The VALHUDES protocol aims to compare the clinical accuracy of HPV testing on vaginal 
self-samples and first-void urine specimens collected under standardised conditions, with HPV 
testing on matched clinician-taken samples. 
 
Self-sampling is becoming increasingly important and applicable to supplement organised 
cervical screening program or as screening modality in areas without organised cervical 
screening. Consequently, diagnostic test accuracy studies should preferentially be conducted 
in the setting where it is intended to be used. However, empirical evidence indicates that the 
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relative accuracy of self- vs clinician-taken specimens is robust and translatable from referral 
to primary screening settings[15]. This finding offers the methodological basis for 
VALHUDES, which generates two major advantages: efficiency and avoidance of partial 
verification bias. Partial verification bias typically arises when unequal proportions of test-
positive and test-negative subjects are submitted for verification of disease status with a valid 
reference standard[42,43]. More CIN2+ patients are found in a referral population such as a 
colposcopy centre than in a screening population, which increases the power to address 
sensitivity hypothesis. Moreover, in a colposcopy centre, it is straightforward to apply the 
verification of disease status to all enrolled patients, and consequently, the problem of 
verification is avoided. Partial verification and methods to control its impact by referring a 
random fraction of screen-negative subjects for disease verification by colposcopy/histology, 
imply major methodological and statistical challenges in screening studies[42,44-47]. 
 
Reflex cytology combined or not with genotyping for HPV16/18 are recommended in several 
guidelines for management of hrHPV-positive women[48]. Whereas HPV16/18 genotyping 
can be easily applied on self-samples (vaginal and first-void urine), cytology on self-samples 
is not recommended due to the substantially lower sensitivity compared to cytology on a 
clinician-taken specimen[49-51] and the higher rates of suboptimal sample adequacy[49]. 
Consequently, molecular rather than morphological triage approaches obviate the need for an 
additional clinic visit for women who are hrHPV-positive on their self-sample which is likely 
to compromise the efficiency of a strategy offering self-sampling kits to unscreened or under-
screened women. Identifying molecular methods applicable to self-samples that serve as a 
triage of hrHPV-positive women is therefore considered a priority for future research. 
VALHUDES studies could be easily extended to incorporate a triage component, where 
aliquots of hrHPV-positive women are tested for promising markers such as methylation of 
certain viral or human genes or micro-RNA profiles which are associated with progressive 
HPV infection and neoplastic transformation[23,52,53].  
 
Urine collection might be more socially and/or religiously acceptable or simply more 
comfortable for some women who are reluctant to perform vaginal self-sampling. Offering an 
appropriate kit for collection of a vaginal self-sample or a first-void urine sample might be 
particularly suited in settings when directly provided to patients, e.g. during a visit to a primary 
care service, who are identified as not screened. A small trial conducted in a group of general 
practices in Brussels reported a 78% response rate when a vaginal self-sampling kit was offered 
directly to women not screened since three year or more[54]. Large-scale trials should be set 
up to confirm these promising results. Offering a self-sampling instrument to eligible patients 
in contact with primary care services might simplify the logistics of mailing devices[55]. 
 
This VALHUDES study can easily be reproduced in other countries and settings and may assist 
in facilitating the generation of more comparative data sets for different combinations of 
defined self-sample device and HPV assay combinations. We invite researchers to conduct 
other VALHUDES-like studies which could then be pooled in individual-patient-data meta-
analyses. The demonstration of similar sensitivity and specificity for CIN2+ of a given HPV 
assay on a (vaginal or first-void urine) self-sample taken with a particular device compared to 
a sample taken by a clinician could be a plausible validation principle under the condition that 
the HPV assay fulfils international requirements for use on clinician-taken cervical 
specimens[13]. 
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